Sanjay Mehta, M.D.
Appearances
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You're in a zone where there's a principle we talk about, it's called ALARA, A-L-A-R-A, which is as low as reasonably achievable. And that's been the mantra for our radiation safety people, the Nuclear Regulatory Commission and whatnot, that you want to keep things as low as possible. But having said that, when you're talking about numbers of less than 50 millisieverts,
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's kind of an arbitrary number. I should have maybe gotten a test actually when I had my cough last time, but I just don't want to do it. I don't want the exposure. But it's so minimal in terms of biologic effect that we really don't even really worry about those, even if it's getting one of them a month or so.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And a big reason for that is a lot of these numbers, especially the 50 millisievert number, is extrapolated from higher exposure rates. There's something called a linear no-threshold model, or LNT, and that's been written about extensively, and that's what we're all taught in radiobiology and residency.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
One-fourth of my radiation training in residency was actually radiation biology, in addition to clinical oncology and radiation physics. So the linear no-threshold model is what states that we know based on all the data from nuclear fallout from Chernobyl, from Three Mile Island, of course, from Hiroshima and Nagasaki, from the bombs, that
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
At a certain dose exposure, there's a certain risk of developing a cancer or any other endpoint, whether it be dermatitis or bone marrow suppression. These numbers are well sorted. But when you try to extrapolate lower, so you take maybe, say, a dose of one full sievert, the 1,000 millisievert, and you start extrapolating that lower and lower to where you're looking at 100 or 50 millisieverts,
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The linear model assumes that there's some level of damage even at those lower levels. But in reality, there's actually a threshold. The LNT, which is linear no threshold, has actually been proven to be actually erroneous. And so at very low doses, it's actually been shown that there's almost no incidence of any sort of biological damage.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And there's also, it's controversial, but there's animal studies showing there may be a hormesis effect at low, low doses like that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yes. Regular listeners of your podcast know all about hormesis and you talk about in the exercise realm and cold plunges and saunas and whatnot. But the whole idea is doing some degree, a small amount of cellular damage when the body repairs that it actually comes back stronger than it was without the exposure in the first place.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And in animal studies, they've actually shown at very low doses, we're talking about single digit millisieverts here, that they've seen in mouse bones, for example, decreased osteoclasts and increased osteoblastic activity. So the bones actually heal quicker. Some of the soft tissue as well has been shown to actually recuperate much in the way you see in the hormesis from other causes.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's not something that we're claiming is widely accepted, but there is a lot of data showing that that is certainly a possibility, which goes against this classic LNT model. The LNT model itself, the guy that won the Nobel Prize for it in the 1940s did this all on fruit flies, and his work was disproven over the years after that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
A lot of this low-dose radiation safety stuff we have, it's certainly a noble goal to keep the dose as low as possible. But when we get down to these millisievert ranges, I think that they're probably a little bit overblown in terms of the actual negative effects on the human body.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So again, going back to that Alara principle, there's not a whole lot of data at these levels. I certainly would strive to keep it as low as possible, which is what that mantra says. But I would go with the machine that has the best resolution. And if 25 is, if the radiologist tells me that that image is significantly better than a 2.5... millisievert exposure.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Some of the older machines are just less efficient. You may get a better image with the lower dose. I think the dose is pretty negligible. Got it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And the same thing applies. That's on the diagnostic side. On the therapeutic side where I am, our machines are called linear accelerators, and there's a similar progression.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
As we've been able to focus the beams more and more precisely, it's a modulation of the beam, meaning you have a lot of photons being showered in the general vicinity of a patient, but you're blocking out everything except for a small area to treat. And the same way the newer machines do definitely have a lower exposure to the room in general.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Not at all. Not in the least. I would certainly not skimp on dental x-rays, mammograms, if it's someone that needs cardiac workups and things like that. The risk-benefit ratio is so heavily in favor of doing these studies that I don't even think twice about them. I think part of this comes from, you know, I've been doing this 25 years now. I have so many patients.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
By the time they come to me as a cancer patient, they've been through so many CT scans. And nowadays we do PET scans. We follow up with annual PET scans after the fact, which are not only the CT, but you've got a radioactive isotope that's being injected into them. And we just really don't see.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Now, there are certain situations where you are giving, for example, an intravenous therapeutic dose of radiation, say for thyroid cancer or things like that. There's certain new theranostics that are out there. In those situations, you have to be concerned because they can get into the multiple, into a sievert range.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But when you're in these millisievert ranges, it's so important to do these studies. The benefits of mammograms are so proven. Dental x-rays, I don't really think twice about them. Okay.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I think it can be in that range, yes. I think that's exactly right. So PET CTs are relatively new, but up until maybe a decade ago, the PET scan was independent of the CT. They would do them separately.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But the data is so much better when you have the anatomical CT data overlay with the PET that whatever that extra dosage is, I think it's well worth it in terms of the resolution of what we're able to see and what we're able to gain from that information. Okay.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Breast and prostate are the number one and number two, depending on what patient population you're talking about. Prostate may even be a little bit higher.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And this goes back to the 80s when the trend from doing a Halsteadian type of radical mastectomy was falling out of favor and the randomized data was obtained in the 80s showing that a lumpectomy, breast conservation, which is lumpectomy followed by radiation, has the same outcomes in terms of overall survival as a full mastectomy. That's when breast really took off in the 80s.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And around the same time is when prostate radiation started becoming a thing. But at the time, radical prostatectomy was obviously still king. But now in the 2020s, I think prostate has taken off and it's probably close to matching breast cancer now. Those are number one and number two. But we also do, depending on where you are in the country and what you're
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
affiliation with the hospital is tons of CNS, lung, lymphoma, GI, not colon, but more rectal and anal distal GI cancers. Even in the pediatric world, we try to avoid radiating children, but it's a very big part of that as well. So we use it for almost all types of cancer now, actually, all solid tumors anyway.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Fisher's big study in the 80s, which now we have 40 year data from that. And it's interesting how now even the modified radicals are relatively rare. We still have some advanced cases that they have to go that route. But we see tons and tons of patients now who are so much happier. Their quality of life is much better by just having a simple lumpectomy, a central node biopsy.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And if it's all negative, especially if they've had their mammograms, you get a small T1 or T2 tumor. We give radiation to the whole breast following that. And the radiation is, again, fractionated into small daily bits. They'll get somewhere in the neighborhood of, these days, it's actually only about three weeks of treatment, maybe about, I say, 40 gray in roughly 15 fractions.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We used to give, even when I was in a couple of decades ago, we were giving 50 to 60 gray. It was quite a bit higher dose. But to 40 gray in 15 fractions to the full breast, and with the modern technology, we can cover the breast tissue without significant heart or lung dose.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We can even use tangential beams, even if it's a left-sided tumor, to stay away from the heart, which is things that we couldn't do very well in the past. The overall and disease-free survivals are pretty much comparable to someone who had a modified radical.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Fantastic book and one of your best podcasts. Love that guy. Yeah, he's a legend.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yes, in a more advanced case. But if it's a typical T1 or even a small T2 that we see, they may not need any neoadjuvant therapy. They just will If it's, like I say, a one and a half centimeter mass that's easily resectable, they'll remove that just without any neoadjuvant treatment.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And we'll do adjuvant radiation and then potentially, depending on the receptor status, adjuvant hormone therapy, which is the domain of the medical oncologist, but we still work with them. So just surgery followed by three to four weeks of radiation. How long after surgery can you begin radiation? Wound healing, we give them a little bit of time.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We generally do our CT-based simulation and three-dimensional planning maybe two to three weeks after their surgery. And then by the time, it takes about a week to do all of our computer programming, and then we'll start the treatment within three to four weeks post-op.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I usually will see patients for consultation. A lot of times the breast surgeon will send them prior to anything being done. So I'll see them for their initial consultation ahead of time.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But then we plan on doing what's called a planning procedure or a simulation where we're going to put the patient on the table and essentially do a dry run for their treatment, usually a couple of weeks after treatment. And that involves essentially positioning the patient. Typically for a breast patient, they'll be prone with their arm behind their head.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We call it the movie star pose to get the arm out of the way of the axilla essentially. So by putting them in this position and then putting them on a wing board that'll slightly elevate their torso. And there's a lot of different geometry here that we can use. Back in the old days, they had all kinds of ways of doing plaster casts and things like that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But we essentially do now, we'll use a, what we call a vac lock, essentially a bean bag with a vacuum port. And the patient sinks into the bag. We suck all the air out of and lock. It becomes a rigid cast of their body. And that way they fit into the groove that we've made for them. We'll actually form it and mold it around their elbow so they're comfortable.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Many times with patients who've had an axillary dissection, they may have a little bit of scarring, a little decreased range of motion to be able to get their elbow back there. So we'll work with them the best we can. Whatever position we get them in, we do a CT in that position. And that's the position we have to reproduce for the daily treatment.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And the key there is that when they have their arm out of the way, we have to have room so that the machine can move around from different angles. The actual radiation machine has a gantry that can move really 360 degrees, you can treat from any angle you want, but we have to be able to model tangential beams.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We don't want direct anterior field that's going to radiate the breast, but the photons are going to go right into the chest. By using an angle, we can cut across the surface and actually shape the beam to match the curvature of the chest wall.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So we cover the entire thickness of the breast tissue, or even in the case of an advanced, maybe a T4 patient, something like that, we may even do this post-mastectomy, so you're treating the full chest wall. And we go a little deeper below into the ribs into maybe the first inch of lung tissue below that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But by using these tangential beams, that really minimizes the treatment, the photons damaging the lung tissue. So all of that is planned ahead of time.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So post-resection, you'll see a tumor bed. The lumpectomy cavity is obviously clearly visible. It's a fluid pocket on CT. So I'll scan the whole chest. It takes about a week. I have a whole team. I have a wonderful staff, a radiation dosimetrist that helps do the computer planning, and then a radiation physicist that actually calibrates the machine prior to actually starting the patient.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So we do the scan. Of course, the CT scan is two-dimensional slices, but we have three-dimensional modeling software. So I have a full 3D model of the patient I can look at from any angle. The slices are how thin? It varies. This is not a diagnostic scanner thing. So usually something like two millimeters, three millimeters. We don't have to go super high resolution.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
This is true.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so that way, once it's reconstructed, then I can have a nice idea of what angles to bring the beams in at. Because every person has a slightly different curvature to the chest wall. You're going to have to customize the anatomy. different breast sizes. We have all kinds of different techniques.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I won't go too much into the details, but if someone is very large-breasted, we could even treat them prone, have a special pillow to allow the breast to hang down.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's true, but our technically what we call the clinical target volume, the area that we're trying to radiate would actually include the entirety of the breast tissue, even all the way down to the chest wall. So there's two different ways. There's full breast radiation, which is what most people get. But what you're describing actually is partial breast.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We would just target the lumpectomy cavity. And that can also be done. We save that for usually for older women who have a very small tumor. And when I say older women, it's more because of the fact that the remainder of the breast remains untreated. So a local recurrence is a little bit more likely in someone that has not had full breast radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But in a selected subpopulation of small breast cancers, in someone with a very large breast, you can do partial breasts where you're only targeting the lumpectomy cavity. But for most of our patients, we actually do treat the whole breast as standard of care, plus or minus the axilla.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's where the pathology comes in, because if they did have a positive lymph node, then we have to go after the axilla and sometimes the supraclavicular and even intramammary nodes in some cases.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
When they're actually on treatment, it's about 15 minutes, sometimes even a little bit less than that. Some of the newer machines can deliver the beam even faster. But when I say 15 minutes, I'm talking about, I have four patients an hour typically. So in and out of the room in 15. So that includes getting them on the table, The key thing for accuracy and reproducibility is positioning.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the reason we made that mold and we've not only did we get them in position, but I've also got a couple of dots on their skin to use as reference marks to make sure that the patient is in the correct position. That whole process probably takes five minutes every day when the patient gets in the room and then maybe another five to 10 minutes for the actual beam to be on.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And my favorite thing is to come in the room after the patient's first treatment. And then the most common question I get is, hey, doc, when do we start? And I'm like, no, ma'am, that was, they're like, really? That was it? Because the patient feels nothing. So the machine will go through its various angles. It's pre-programmed. The entire process is about 15 minutes a day.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And they can leave feeling the same as when they got there, just like getting any x-ray. They jump in their car and go right back to work or to the gym or the golf course.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So I was in residency in the late 90s, early 2000s. So it was a very interesting time because we were at the cusp. My first year of residency, and I was at UTMB in Galveston, it was a combined rotation with MD Anderson. So we were at a time, this is 1998, we're talking about where At the end of the old era, we didn't even use CT planning.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We just had a couple of orthogonal films and we were literally drawing our tumor volumes out with a grease pencil on a physical x-ray and using that cutout to go trace a styrofoam negative and make a metal or a lead alloy block, which you would slide this basically this aperture in the path of the beam. That's the way it was done for decades.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so we were still doing that when I started residency. But by the end of residency, we had full-on CT planning where now we're doing a full CT scan, doing everything virtually. And of course, it's far more precise and you can model multiple different iterations. Okay, do I want a beam coming in from this angle? Do I want to bring in an orthogonal beam from here?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Do I want to block out a little bit more of the chest wall to get the heart dose down? I can see all that stuff now. So by the time I finished residency, we were basically doing what we do now, albeit with much slower computers and Just being in the infancy of that, it was probably more like 20 to 30 minutes per patient.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But the last 15 years, roughly, to answer your question, things have been much more automated. And instead of having lead blocks that you're sliding into the path of the beam, now everything is shaped in the head of the beam by our computer. So you hit a button.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And when I've already programmed the treatment planning values, the machine knows how to shape the beam to match the aperture of whatever you're trying to do. So that's all fully automatic now. So the therapist job, we have a radiation therapist who actually positions the patient in the room. They get them in position.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They take a picture x-ray first, either a cone beam CT, which is a low-dose CT, or just a PA in a lateral film. And we actually overlay that with our planning imaging to make sure that the original reference from the planning day matches today's image. The machines will actually superimpose the daily image with the reference image. So everything is automatic. I can see, okay, are we directly on?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
If everything lines up correctly, then we literally have two images that look identical. I just see one image, which if it's slightly off, if there's even a few millimeters this way or that way, we account for that by moving the table. The table is motorized.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the patient will be laying there and they'll feel it move just a few millimeters this way or that way until we have perfect concordance between the daily setup and the original. That's really, really improved our accuracy. And the regional miss, the geographic miss, which was a problem in the old days when we didn't have digital imaging and all this stuff, is essentially gone now.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yeah.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So that's another thing that has changed. Now, essentially, when I say now, the last basically 30 years, most machines in the US are linear accelerators. So these are artificially generated x-rays. It's essentially accelerating electrons through a long vacuum tube, essentially an electron gun. And at the very end of the tube, you've got a tungsten target.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so the electrons hammer that target, and then they shower photons out. So you're generating the X-rays that way. And this has been done, actually, I think your alma mater, Stanford, had the very first one in the U.S., the medical linear accelerator. But prior to that, they were using these for atom smashers, and they have the gigantic machines that were used for physics.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But they started in London, I think, in 53. And then I think in the late 50s, Henry Kaplan at Stanford had the first one. So we're essentially still doing that even today, what, 70 years later. But the key difference is how we're able to shape those photons once they come out of the machine now. And so when the actual photons are coming out, they're completely unfiltered.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It comes out in a cone shape and it diverges just as any light source would. You know how when you hold a flashlight to a wall, you get a nice precise circle. As you pull the flashlight away, it diverges. So we have filters and we have what's called the multi-leaf collimator that can actually shape the beam, as I mentioned earlier, that can actually match the anatomy of the patient.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But now that's all done. Automatically, we programmed it ahead of time as opposed to the old days when we had to use lead blocks that were actually physically blocking the beam. But basically, the LINAC has been the standard. Prior to that, we were using a Cobalt-60 machine, which is essentially, it's not even a machine.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's basically just exposing a patient to a radioactive isotope and then shutting the jaws again. And actually, those are still in use in most of the world. There's a few left in the U.S., but they've mostly been decommissioned now because the LINACs have taken over.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So roughly 2.5, 2.6 gray per day. And you're right, times 15 treatments. So you're getting roughly 40 gray to the breast. And then we usually actually do a boost. So we'll give what we call a tumor bed boost. We give a little extra dose to just the lump itself, the lumpectomy cavity itself.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And there was a couple of French trials that showed that adding an extra 10 gray over an extra five days, so two gray times five, just to the lumpectomy cavity itself improves local control over just the whole breast.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
An extra boost. It's a customization based on the patient's pathology. I'll occasionally have a patient that the breast surgeon will call me and say, hey, Sanjay, we did our best, but we had a persistent positive margin. I went back and did a re-resection and there's still a positive margin, or maybe the positive margin is at the chest wall. They can only go so far.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
In that case, instead of giving a 10 gray boost, I might give a 16 gray boost or something to account for instead of just treating microscopic disease, potentially macroscopic residual in that sort of situation. So every patient's a little different. And then the axillary nodes themselves are normally not treated in an early stage patient.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But depending on the risk factors, if it's a very large tumor or if there was a positive central node, maybe an incomplete axillary dissection, in many cases, we end up treating the full axilla. And in some cases, when it's advanced disease, we end up treating level 2 and level 3. So you end up getting the superclav as well.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
This brings up a point I need to kind of emphasize. It's not so much the total dose, it's the dose per fraction. So how quickly are you getting it? So the standard of care was actually 50 gray rather than today's 40-ish gray, but it would usually be given in two gray per fraction daily doses rather than the 2.6, 2.7 that we're using now.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the effective dose, when you take into account, there's a whole radiobiology lecture that we're not going to bore people with, but taking into account the dose per fraction and the total dose, the biologically equivalent dose with the BED is roughly the same now at 39.9 gray given in 15 treatments versus the old 50.4 gray that was given in, say, 25 to 28 treatments.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So it was a longer process, you're right. And we still do that in some cases. And this comes back to another question you asked about, about the homogeneity of the dose. And so our goal, of course, is to have 100% coverage of the whole breast.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But the reality is the way that photons are going to be interacting from different beam angles and whatnot, you're always left with hot spots and cold spots. And so the biggest difference between what we're doing now versus the old days wasn't so much the total dose, it was the actual homogeneity that you touched on.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the heterogeneous old way of doing things with a cobalt machine or with a low-energy x-ray unfortunately meant that there were hot spots and cold spots in the breast. And that, of course, could either be manifested as scar tissue if it's a hot spot or, heaven forbid, a geographic recurrence if there was an area that was underdosed.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So with the modern computer planning, we're much more homogeneous. So even though you may say, I got 50 gray back in 1995, and now I'm getting 40 gray, you're now getting 40 gray in two and a half gray fractions, which is equivalent to the old 50. Plus, we don't have 150% hotspot and a 60% cold spot. We have a nice 100% match all the way across. It's like a CAD cam type of thing.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I'm about as close to an engineer as an MD can be. And so we do actually simulate the dose distribution of the radiation in the tissue. In modern days, we get a nice homogeneous dose. And therefore, that goes to your next question, which was, what does the patient experience?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Maybe not so much 20 years ago, but more like 30, 40 years ago with the older cobalt machines, they would get a terrible dermatitis. Many times it was moist desquamation confluently over the whole chest wall. Axillary desquamation is always bad because of the friction of the arm.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But with the modern treatment now with, first of all, not using cobalt, using linear accelerators, the energy of the photons is higher, which means the skin dose is slightly lower. So you're getting maybe 100% on the skin rather than 150% like you once did. So we don't see anywhere near the skin reaction that we used to. It's more of a maybe a grade one or a grade two erythema.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So mild redness or maybe sometimes a little bit of sunburn, but nothing as severe as we used to. So these days, patients do still get a sunburn. We give them a little free samples of Aquaphor.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They can use an aloe vera plant if they have it, just your normal type of skincare stuff, as opposed to the old days when we were actually treating essentially burn victims with silver sulfadiazine and heavy-duty narcotics and things like that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The modern era, it's so much better that a lot of the patients, especially if it's someone that doesn't have a very large breast, there's less energy being put into a smaller-sized person. They don't get anywhere near the skin reaction. And that's why if you did have a very large patient, we actually still use the old 50 gray in 25 because you're giving less dose per day.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And you do have a very large breast where you're going to have areas that are going to have hot and cold spots. Sometimes that's still needed. So we have to tailor it to the individual is, I guess, my bottom line there.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
There certainly is. And so the problem was, is that in the old days, you didn't have computer modeling. And actually the old school physicists got to give your hats off to those guys that had slide rules and probably abacuses or whatever the heck they had back then. You couldn't really tell exactly where the hot and cold spots were by actually having a computer show you.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's one of the youngest fields, too, in that respect. It's not steeped in some of the traditions that surgery and medicine are. So, yeah, it's a new field, highly evolving very rapidly, and the technology has changed so much just in, really, in the last decade or two.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You had to go based on the fact you choose a photon energy and you know what the dose distribution at various depths is. And so you would try to minimize that by, again, having beams coming in from different angles. And then by using multiple angles and multiple fields, you could paint in the dose as best as you could. But
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yes, certainly there were issues where as you get deeper into the tissue, the dose would be lower. And then this is, again, before my time, but there certainly were studies showing that there were geographic misses. That was obviously not good, which sometimes would lead to like a salvage mastectomy or something like that. But in the modern era, not so much.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They're back in vogue, right? The silicone. Either way, the x-rays we use, they are not at all affected by that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I think most of them we see are actually under the muscle. Even recently, but I've seen them both. Even now, the plastic surgeons have different criteria for that. But regardless of what it is, if it's under the pec, then of course, it's really a little farther away. It's not a huge issue, but the radiation will still affect that area. But typically, these implants are pretty tolerant of that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The only issue down the road is they may have a capsular contracture or something from fibrosis. The bigger challenge we run into is for our post-mastectomy patients who are going to be reconstructed and they have expanders put in. And that's where the relationship between the radiation oncologist, the surgeon, and the plastic surgeon is key.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Explain to folks what expanders are, how that works surgically. So essentially what's happening is when you have a full mastectomy, if a patient wants to have their breast reconstructed later on,
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The breast surgeon will remove the breast, but then the plastic surgeon will come in and place some sort of a placeholder to allow the soft tissue and all the connective tissue and the skin to stretch to allow for future implant placement. And so those tissue expanders, they can actually inject saline into them with a port and gradually stretch them with time.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's normally what they would do if there was no radiation involved. Again, most mastectomy patients really don't need radiation because this gets away from what we mentioned earlier where breast conservation is lumpectomy only. But there are some patients with a full mastectomy who are going to get reconstructed. So they come to me when I do their CT scan.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They have this expander in place from the breast surgeon. So we have to, again, modulate the beams and we treat the entire chest while we make sure we're covering everything.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But simultaneously, we have to make sure that we don't have those hot spots in the area of the expander where potentially you could cause scarring and fibrosis and cause the expander to have to be removed, have the plastic surgeon have to revise it. That becomes a whole nother hill of beans there that we don't like to mess with. But we have techniques now to be able to keep the dose off of them.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And again, as you mentioned earlier, whether it's silicone or saline, it's roughly the same density. But some of these tissue expanders have bits of metal in them. They may have other artifacts. And so when I'm treating with photons, with x-rays, depending on what you're hitting, the effect is based on the density, the atomic number of that tissue. So metal behaves very differently.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Bone behaves differently from air, but when you're in the spectrum of saline, tissue, water, it's all basically the same. We can model all that very much like, I'm getting ahead of myself, but very much like when we have a prostate patient with a prosthetic hip, a piece of metal right next door, we're able to compensate for that with the modern computer treatment planning systems.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
As a kid and growing up in Houston, some of my family friends were radiologists. And I remember just like probably an elementary school kid that some of them were talking about radiotherapy. And these were diagnostic radiologists who at the time, CT scanning was pretty new in the 80s. Prior to that in the 70s and then prior to that, it was kind of just a fellowship.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Not at all. The only time we see radiation patients who have nausea or vomiting, it's a lot of times for other sites, they may get concurrent chemo radiation where the chemo could be responsible. But for breasts, we don't do concurrence, usually sequential.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The only time I really see radiation-induced nausea is if I'm treating an esophagus or a pancreas or something that's treating in the abdomen or somewhere along the GI tract where nausea is more of an issue, typically not for breasts.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The answer to that has been evolving. There was a time as recently as probably 20 years ago where we only treated patients who were probably medically inoperable that the urologist would say, hey, you know, this is a high-risk anesthesia patient. Let's send them to Dr. Mehta for radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And that's a big reason why a lot of the older data was not as good for radiation because of the patient selection criteria. But in the modern era, as we've gotten more and more precise and our side effects have gone down and our cure rates have gone up, now it's pretty much wide open where pretty much anybody who's eligible for surgery would also be eligible for radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So there's not that big of a divergence as there once was.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
He and I may have another text thread in case our teams meet in the playoffs as well. He's a big Ravens fan, and I'm from Houston, so I'm hoping we get there.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So to answer your last question first, androgen deprivation for high-risk disease is certainly standard of care. Gleason 8 or higher for sure. The Gleason 7s are always a gray zone. And so a 4 plus 3 with high-volume disease typically also do get concurrent and adjuvant androgen suppression along with radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But one of the things that's really changing now is I know Ted talked a lot about with the Decipher score where they can look at the chromosomes of the actual cancer cells and have a much more granular view of exactly are they truly high risk or can you say that this one 3 plus 4 is more like a 3 plus 3. So for a lot of the 3 plus 4s now with the Decipher test, And there's also an AI test.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I know you had a really interesting discussion with your AI expert, and that wasn't too long ago, called Arterra. And we're using that. That's actually in the NCCN guidelines now, so that Arterra test can help us differentiate between a unfavorable and a favorable intermediate risk patient. I treated my own father not too long ago. He was the first person I did this on.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Radiologists would have a Cobalt 60 machine that they would train on for a few weeks and you do a few easy calculations and do some crude treatments. But it really started, it came into its own starting in the 70s and really more into the 80s. And that's when it became its own discipline. The ACR had a separate carve out. And so our residency training is completely independent of diagnostics now.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The arteri test is essentially, they just use the actual images of the H&E slides that were already done from the pathologist. And it's interpreted by a machine learning computer that has been trained on hundreds of thousands of prostate images from the old RTOG studies, the 94s, all the stuff that was done back in the 90s.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And it can now come back and say, okay, very much like decipher, it can say that this is a 3 plus 4, but it's a favorable or an unfavorable person in that subgroup. And so because of that, we can stratify better and actually tailor it to where maybe a 3 plus 4 doesn't need androgen ablation at all.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And maybe even some four plus threes, if they come back low enough on the scale, you always have to talk about the side effects and whatnot. But the standard of care was always to give concurrent androgen ablation for intermediate risk. But now we're able to really take some of those people out of the equation with these new studies.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Those are number one and number two. Yeah, lack of incontinence and lack of impotence. But of course, when you have androgen ablation, that clouds things a little bit. But typically, the number one thing we see is patients who don't want to deal with diapers.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And for the most part, although incontinence is still described to some degree in the literature, in my personal experience, I don't think I've seen a single patient who came in continent who left with anything less than that. There's no pads, there's no nothing. And then, of course, as I talked about with breast cancer, we can also focus very precisely on the prostate itself.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the dose to the penile bulb, the dose to the rectum, the dose to the bladder are so low now that the side effect profile is essentially zero from a radiation standpoint. Now, they may be having hot flashes from the androgen deprivation and decreased libido and fatigue, as you know.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But on the radiation side, because we have all these tricks now, very much like with breast, the way we can avoid the heart and the lungs, in the case of the prostate, we can almost completely avoid the bladder and the rectum and even the penile bulb now. So the quality of life, those are the reasons why people tend to choose radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
In fact, I think Ted had mentioned in his last talk, there's a gel spacer that is often inserted. It's an injection that's done transperineally, and it separates the rectum from the bladder. But in my years of doing this, when you're very diligent about how you do this, very much like a surgeon pays attention to the details, so do we.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I can actually trim the dose off of the posterior prostate and just make sure the dose fall off between the posterior prostate and the anterior rectal wall is so rapid that the anterior rectal wall is always going to get some dose, but usually it's not clinically significant.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And what we do to manifest to make sure that that is a daily thing, because we're talking about treating patients for multiple weeks, we actually coach the patient to come in with a full bladder and an empty bowel. And by being diligent about that and imaging daily to Double check that, in fact, the bowel is empty and the bladder is full. That allows those two organs to separate from the prostate.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So we just do, it's an intern year followed by four years of radiation oncology with a little bit of overlap, but not a lot of diagnostic training at all, just because there's so much to do just on the therapeutic side.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And even a few millimeters of separation is all we need to take advantage of our modern focused radiation beams.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Not so much for pelvic patients, but we do that for breast cancer, especially left-sided breasts. So just to go back to that, you actually have a deep breath hold, which will get the chest wall away from the heart. So we do that in the case of thoracic tumors, but in the pelvis, the diaphragmatic position doesn't really make any difference.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's more about bladder and rectal filling and emptying, respectively. That's much more important.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I get that question all the time. And from a LASIK standpoint, I think I would be worried about it. That's probably why I'm still wearing these Coke bottles, unfortunately. Yeah. But in the case of prostate cancer, first of all, the dose is given over the course of several minutes. And then each of those fractions is, again, talking about one fraction out of multiple weeks.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So even if someone absolutely had a coughing fit or something like that, first of all, we're watching them. We can stop the beam. You can stop it at any given moment, but slight variations day to day. The biggest variations are going to be based on bladder and rectal filling. We take that into account when we're doing the treatment planning.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So there should really be no adverse outcome because what I actually do is I'll map out where the volume of the prostate is and we will actually purposely expand that volume and treat the full dose of radiation, even a few millimeters outside of the prostate to make sure that there is any internal organ motion or anything like that, that we take that into account.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But typically if someone's coughing or something like that, we'll just hit the pause button and get them reset. And ultimately it's not an issue.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Typically, the urologists have already screened the patient. Everyone's first exposure is going to be to what the urologist tells them. And luckily in this day and age, I'm lucky we have people much like Ted who are very open and who are very open to not just doing surgery, but who actually look at the other options and present everything to the patient.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But typically a patient who maybe was medically inoperable will certainly come to me. But even somebody who maybe is on the borderline who wants to see both sides of the token, a general urologist will send them to a surgical specialist and to me. And we'll go through all the pros and cons of everything. And really what it comes down to, to not belabor the point, it comes down to two things.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You want to be cured. Cure rate is key. But quality of life is equally important, if not more important for most people. And so now that cure rates with our modern focused radiation allow us to get such a high dose into the prostate, we can say that they're essentially equivalent to surgery. So we don't have that deficit like we did 20 years ago when our fields weren't as precise.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It was sort of the shotgun approach versus our sniper approach. Now, because the cure rates are better, then it really comes down to the quality of life changes. And that's where there's a spectrum of things.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That comes to a key point where it's trading one thing for another. You don't have the incontinence. You don't have at least the short-term risk of impotence like there is from surgery. You don't have the penile shortening or whatever other sort of things that they have to deal with. But you have to deal with hot flashes and decreased libido and whatnot.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But again, most of the patients who are intermediate or high intermediate risk are going to, if they end up not having a negative margin or a seminal vesicle invasion after prostatectomy, they're still going to come to me for radiation anyway. And they're still going to need to be on androgen ablation. So there's a significant number.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Now, these days, we'd certainly treat a lot less Gleason 6 than we used to. We observe most of them. But there's a lot of Gleason 6 folks that even in this day and age will choose to have radiation just because it's maybe a little bit more aggressive form of watchful waiting. And in that case, there is no androgen ablation and they just glide through the whole process.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
People don't die from Gleason 6 disease, as we all know. Because quality of life, they do so well with the radiation. There is just less of a chance of it progressing to a seven. And when they come to me, it's interesting the different patient populations.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I also get people, this is not mainstream, but I get a lot of transplant candidates who need a renal transplant and they cannot get their transplant unless they're cancer-free. Even if it's one core of a Gleason 6, they're ineligible for their transplant. So those guys I will certainly treat, but I've been following them now for 20 plus years that we've been doing it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
quality of life they do so well. And this way they don't have to worry about androgen ablation when they do become a Gleason 7.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's why these haven't been done. You would need decades to do a trial like that. Yeah, it's a 20-year study. But it certainly would be interesting to see what it would show. But the real-world observational studies show that all the Gleason 6 guys, I would say until maybe a decade ago, we did a lot of Gleason 6 patients. They mostly were sent for radiation. Why were they sent?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I guess it's a combination of different things. People have different levels of tolerance for watchful waiting. in the pre-MRI days, everyone had to have an annual biopsy. And that alone is more anxiety invoking than really the radiation is. Not to mention, we'd see a fair number of folks with urosepsis and complications from that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So now in the MRI era, we don't really see that anymore, but that was done very routinely. And because the patients had so little proctitis and cystitis, especially in a Gleason 6, where not only am I not worried about pelvic lymph nodes, I'm not even really worried about the seminal vesicles.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So my field is very small, which really minimizes the side effects because the bladder, a full bladder, when it's actually full, it'll move superiorly and anteriorly where the dose is close to zero. So most of these patients, they just kind of laugh and say, I'm coming in for my daily treatment and I'm right back to my normal life again.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
In the absence of androgen deprivation, radiation has become very simple for prostate patients now.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That answer would have been zero probably five years ago, even as recently. But now with Arterra and Decipher, it's probably, I'd say, a quarter of them don't need it. If it's a 3.4 with a low decipher, low arterial score. And again, this is still an evolving area where I don't think anyone has the exact answer, but that's what most people are doing nowadays.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And even some 4 plus 3s that have low deciphers are potentially candidates to avoid that. And the biggest change in this has now been our ability to do PSMA PET scans to follow up. Because otherwise... I think that the extra androgen deprivation was more of a band-aid for not being able to see what's going on afterwards.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Now, if someone has a recurrence and you do a PSMA PET, I've got a guy that had treatment 20 years ago with radiation. Now he's rising PSA. Otherwise, he'd just be stuck with ADT for years. Now I see a positive periaortic lymph node on a PSMA PET. I can just treat that area and very successfully. There's no long-term data yet, but it seems to be working really well.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Similarly to how we would use a FDG PET to target a lung tumor in the past.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
No, let's say, okay, we could talk about that or we could talk about post-treatment three years later. So post-treatment three years later, palliative radiation does work very, very well. It would be probably five treatments. You can even do what they call SBRT, which is stereotactic body radiation, maybe in a single fraction. And it definitely is very good.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We kind of joke about it and just kind of spot weld that spot where it's not going to prevent something else from popping up elsewhere. But that's extremely well tolerated and usually it'll stop the progression at that site.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So there are people who had high-risk disease, and to get back to what I mentioned earlier, if they had a couple of spots like that at the time of initial diagnosis now, it's been shown that you can treat the oligometastatic disease if it's in the bone only at the same time as the primary lesion, and the outcomes are actually not significantly worse if it's just limited disease.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Actually, I had a guy walk into my office with a PSA of 1900. He looked just as good as you or me. I actually took him on a TV show I did many years ago. It was kind of an interesting story. 1938, 65-year-old guy, Mr. Macho, had never been to a doctor in his life, widower who decided that he was dating a younger woman now. And she's like, if you want to be with me, you got to go get checked out.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Colonoscopy clear, blood work all clear. Oh, by the way, your PSA is 1900. Which means the lab made a mistake. I mean, that's what you would think. Yes, that's what you would think, except for his bone scan looked like a Christmas tree. And this was in the pre-pet era. I mean, he had disease in every bone in his body with zero symptoms. So this is an outlier situation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But in that situation, you need lifelong androgen deprivation and chemotherapy. Back then, it was mostly taxol-based therapy. We didn't have all the second-generation drugs. androgen ablation drugs that we do now, like enzalutamide. But at that time, when we saw that, you know, he went and got chemo and got androgen ablation. When he came back to see me, fully functional guy, perfect shape.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
His PSA was down to 1.5 with just the systemic therapy. And at that time, the tumor board, we presented him, the decision was made to go ahead and treat his prostate as though he was a de novo presentation because all the bone disease had resolved. He did great. So you treated his prostate and how long did he live? He's still alive. This has been, I got an email from him just about a year ago.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So I think he, at least as of a year ago, he was 12 years out, still doing great with zero side effects. He's on androgen ablation for life. So he's certainly going to have issues from that, but overall still very functional. How is this possible? What's the biology of that tumor that allows him to still be alive? I don't think it's even necessarily just prostate.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I've even seen it in breast cancer patients. In the small subset where it's bone-only disease with no visceral metastases, some folks can live for a very long time with bone-only disease. And I'm not sure what the answer to that is.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You would expect that at this point, but no, not even one.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Now he's in his, yeah, late 70s and has not fractured a thing and is still active. The guy plays golf. I hope he still has that young girlfriend. I'm not sure about that. But other than that, other than the hormonal aspects of it, yeah, it's amazing. I've seen many, many people with four digit PSAs that we get them down at least NED for some window of time, even if it's not that long.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yeah. I think the highest I've seen is 7,500. That was a person that ended up passing away. But the guy who was 1,900, I think a lot of it is a function of just like any other type of tumor. He had all the other risk factors that were lined up. He was young, healthy, no other comorbidities, active.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Rampant metastatic disease. Right, right, right. And that's the thing. You get some of these really poorly differentiated cancers that no longer resemble their prostate progenitor cells. They're very hard to monitor. And a lot of them even don't even show up on a PSMA PET scan.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
radiation itself, the term itself has got a bit of a negative connotation, but basically it's part of the electromagnetic spectrum. So we have everything on the one in the range of increasing energy of photons, which are just particles of light. On the one end, you have radio waves and microwaves. On the other end, you've got infrared and, excuse me, you've got
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's difficult in terms of actual metrics, even for the surgeons. Like, you know, TED is excellent outcomes, but it's not like it's a published series.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
True. So it's a handicap right there. It's a handicap right there. 100%. It really comes down to finding someone who's got the experience. And in my case, because we do so much prostate, I think I've done something close to, in the modern era, 7,000 cases, probably 10,000 when you include the pre-image guided radiation days. Someone who specializes in the area that the cancer is located.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So someone like me, I may be extremely experienced in breast and prostate, but maybe for a pediatric malignancy, you're not going to come to me. You're going to go somewhere else or a CNS or something that's unusual. You have to find the right tool for the job. But you have to just interview your doctor. I don't think there's anything specific to radiation. And asking about complications.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I think being very open with them and saying, yeah, exactly. And so ideally, maybe you come to someone who knows something. Like I get a lot of patients who aren't familiar with the field, but they'll have a patient. They'll have a family member that's a nurse or a dentist or a veterinarian or whatever it is. Someone that has some medical background, they can say, okay.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Let me ask the more specific questions. And these days with the internet, you can do all kinds of research in terms of when I'm talking about matching my volume of the dose distribution to exactly conform to the tumor volume. That's something that's very easy to talk about. But I mean, for an educated patient, they can ask to see the actual computer simulations.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
A lot of my engineering patients- I was just about to say, engineers probably have an easier time than- They do. And my engineering patients are really the only ones who do this. I usually pull out all the graphs. I show them dose volume histograms of area under the curve for each organ. And you can see, okay, the prostate dose area under the curve is huge.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The dose to the bladder and the rectum is super low. You can actually quantify that. But for a lay patient, it's hard. It's not that easy to do that. I think a lot of it you have to go with your gut, too, in terms of this guy's had a lot of experience. And the initial consultation is where it all comes down.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I'll spend an hour with a patient and go through every little nuance of what could and couldn't happen. And my main MO is to sort of over-prepare them and have them be pleasantly surprised maybe when the side effects aren't as bad rather than the other way around. It's hard to find the right person, but there's a lot of good doctors out there, so...
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Sure thing. The main differentiating factor for brain patients is whether it's primary or metastatic disease. And although primary brain tumors are relatively common, they are dwarfed by metastatic disease. So the vast majority of what most radiation oncologists see when you're treating CNS is going to be usually lung, especially small cell-based brain metastatic disease.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
ultraviolet and then you get into x-rays and radio waves. And in the middle of all that is the visible spectrum. So when you see, I'm sure everyone's seen the graphs where you've got the rainbow, red, green, blue that we can see, the human eye can only perceive a tiny little narrow spectrum. These are wavelengths.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so in those situations, the trend used to be where everyone would get whole brain radiation. But now with the advent of stereotactic radiosurgery, which is more focused, precise radiation, the newer data shows that you can actually just treat the area of metastatic disease as delineated on an MRI scan and not necessarily radiate the whole brain like we used to.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But for decades, everyone got whole brain radiation. And for the most part, they did all right. But the problem was you're looking at a patient population that maybe doesn't have that much of a life expectancy. Now that systemic therapy, immunotherapy, everything has gotten better, especially in the case of lung patients, they're living longer.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We have evolved where we've been finding people that were previously radiated to the brain were having cognitive issues years down the road. Not for the short term, they would tolerate it well, but maybe they'd start to have more forgetfulness, an inability to remember numbers and names and whatnot. And this was from whole brain radiation? Whole brain radiation. And give me some doses.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So we're talking about 30 gray to the whole brain given in 10 fractions of three gray each. Three gray times 10 was a sort of a standard thing.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And that's to the brain. So it's a different story.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
No. So the only difference between sieverts and gray in any patient is going to be whether we're talking about dose in tissue or coming out of the machine, basically the dose in air versus dose in the patient. The biggest thing with brain tumors, yes, the bone certainly is going to attenuate more dose, but what I'm talking about is actually 30 gray into the brain itself, the actual brain tissue.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
A little bit more.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's not like they're wearing a football helmet or something. You Yeah, photons can still pretty much go through everything. It's not metal. So it'll still go through. The dose is a little higher. And it gets to be like, for example, in a lung patient, it's more of an issue when you have multiple different areas. You got bone, soft tissue, and air.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
In that situation, you have to modulate the dose more. But in the case of a whole brain, it's been found, of course, that the hippocampal dose is very much... related to their cognitive deficits down the road.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So now that we have IMRT, which is a term I hadn't mentioned before, but that's basically intensity modulated radiation therapy, which is also the magic behind allowing us to treat a prostate without burning the bladder and the rectum. And the newest form of IMRT is called image-guided radiation therapy. So you hear IGRT. Basically, those two terms go together.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
These are actually wavelengths and energies which are the very low-end energies you have things like radio waves. In that situation, both radio waves and microwaves are what they call non-ionizing. And I know you've talked about this on some of your previous podcasts. I know you had a really good one with Atariwala from Prenuvo. It was a really nice in-depth discussion.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But by using IMRT, it's kind of like an HDTV versus this 1960s black and white blurry set where we can treat with multiple small pixels and high definition, so to speak. So now when we do a whole brain, if I have to do a whole brain from multiple metastases, by using IMRT, I can literally carve the dose out. I can map out the hippocampus and carve the dose out of there.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So you see these two cold spots on the hippocampi and really have a very low dose there while still treating the remainder of the brain parenchyma. Are there other parts of the brain that you carve out and protect? That's the main one. Of course, we're going to not necessarily completely carve out because when you have multiple metastases, really the whole intracranial space is at risk.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You have to cover everything. So believe it or not, 30 gray sounds high to you, which it is. But for a glioblastoma, we use 60 gray. Granted, that's not to the whole brain. That'll be to the, either if it's an unresectable patient, it'll be the primary mass. And then we will give maybe 46 gray to the peritumoral edema.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But then the rest of the brain is getting much less, hopefully zero in many cases.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's certainly worse. There's, again, multiple confounding factors there because someone who's unresectable probably has other negative issues as well. They have poor overall performance status. They have neurologic deficits. Whatever the reason the surgeon can't operate, that makes it worse.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But yes, even then in that situation, you get probably, again, you're measuring survival in weeks to months. But it's probably double with radiation than without. A lot of our GBMs, though, are resected, hopefully fully resected in terms of at least radiographic, the post-op MRI not showing any enhancement.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
If you have someone that's got a fully resected primary who's a younger patient with not a lot of neurological deficit, they can live a couple of years, actually.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's the key question. I know you and I are both Rush fans. Neil Peart was lost to GBM as well. And it's so many people that's taken away. But I think it just has to do with the invasiveness of the fingers of the tissue in terms of even when you think you've gotten the whole thing, there's microscopic fingers that are always on the periphery.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And you can't just radiate it indiscriminately like you can other parts of the body because you've got the brain there. There's always a fine line you're walking between causing, say, for example, necrosis of the brain versus letting the tumor recur. And so that's really the number one issue.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We do have a new tool now as far as radiation oncologists in terms of treating CNS tumors, which is called proton therapy that you've probably heard about. There's several centers in the country now. MD Anderson, where I am in Houston, has a huge one. But with protons, you potentially can have the dose go into the brain to a certain depth and not exit out the other way, like an x-ray would.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
X-rays are like light. It goes right through you. You may have a decreasing dose, but it's kind of like a bullet. You got an exit wound going out. With proton therapy, this is one of the areas where protons shine because you can actually modulate what's called the Bragg peak of the physics of the protons to where it'll go a certain depth and not go out the other way.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But essentially, the bottom line is that the low-energy stuff that is non-ionizing cannot damage tissue. And that goes all the way up to visible light. Then when you start going to the higher-energy X-rays, that's when you get both X-rays as well as ultraviolet light and then the higher-particle stuff. But basically, the higher you go in the energetics of the particles, the more likely...
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So down the road, hopefully we'll start to see improved survival. So far, it really hasn't shown to be a huge improvement, but there's less integral dose to the rest of the brain. And especially important in pediatric patients where you've got children with growing skull bones, if you can avoid radiating the growing bone to cause a deformity later on that's huge.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So proton therapy is one tool we have, but I wish I had an answer for GBMs. That's going to be a game changer whenever that does happen.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Whole brain radiation is probably, to give you a number, I don't know what the absolute number is, but it's probably 10% of what it was 20, 30 years ago. The original studies out of Kentucky that Patchell had done in neurosurgery Everyone used to get whole brain radiation following resection of the metastasis or even if it was unresectable. And there was some good data back then supporting that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But nowadays, rather than whole brain, you're usually going to do a focused treatment just to a smaller area. And this is kind of a universal trend to less radiation dose to a smaller volume. Same thing in lymphoma. You want to treat just the enlarged lymph node and not the entire lymphatic axis. So it's the same idea where you're trying to minimize side effects.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So whole brain, we still use it in specific cases, like for example, small cell lung cancer. Part of their regimen is going to be once the primary has been treated, if they have a complete response in the thorax, prophylactic cranial radiation, only for small cell. PCI, 20 gray, five fractions, been done forever, shows an advantage. They have lower disease- How much of a reduction in CNS meds?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's a lot. I think it's probably... 70, 80% reduction in CNS failures because they all fail there otherwise. Small cell, they just all do that. And at 20 grade, they really don't have too many side effects. But again, of course, the caveat is always extensive stage small cell lung patient isn't going to have a long-term survival, but at least they won't fail in the brain.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's a quality of life issue.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Basically, I'd rather maybe there's some nuances, but for the most part. Okay, so what's a gamma knife? So gamma knife is, instead of using a linear accelerator, it's actually using cobalt-60, like I described earlier. But you have multiple small sources that can actually be used, very high-resolution cobalt, essentially.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So you're doing the same thing, but instead of using a linear accelerator-based treatment, it's using cobalt. So is that used anymore? There still are centers that use it. It still works very well for what it is, but the focus is very narrow. There's a lot of children's hospitals and all that. I think we're still using it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But the linear accelerator, which is abbreviated LINAC, the LINAC-based stereotactic radiosurgery for the most part has taken over from that because it can do all the same things and also have more flexibility to do more than just CNS. St. Jude's Hospital has a fantastic PD-CNS program and they still have, well, it's been a while now, but they did have a gamma knife last time I checked. Okay.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
exposure to these packets of energy are going to cause damage to your DNA.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I've done a deep dive into this this year, which goes along with all these benign cases that I'm treating now. They're essentially arthritis tendonitis, which we'll talk about. And what's really interesting is that this radiophobia is largely a U.S.-based phenomenon because the first cases, first of all, x-rays were discovered in 1895 by Roentgen.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
In 1898, there was the first case described of actually radiating both arthritis-type things, or ankylosing spondylitis or other arthritis, and also tumors. Even back then, we had no idea how it worked, but there were cases pre-1900 that were already being used for that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And then in the subsequent now 120 plus years, we have this divergence where Germany and the UK, all of Europe really, are using radiation routinely for arthritis and tendinitis. But in the US, it seems to be a basic nuclear phobia, the Cold War, like you mentioned. But another thing that's been talked about, there's a guy named Jason Bechta that has a really good podcast on the subject.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
He's out of Vermont. Standard Oil, the Rockefellers and all actually had a massive lobby group that were actually actively promoting oil over nuclear power plants. The amount of spread went from just the energy industry into just the general zeitgeist of the entire country. And so at that time, the radiophobia just caught on.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And it was, of course, bolstered by World War II and seeing what happened in Hiroshima and Nagasaki. And then on top of that, you've probably heard about the radium dial workers. There was a movie, it's actually called the Radium Girls. These are essentially women in the 1920s that were using radioluminescent phosphorus paint to paint the watches. Watch dials, yeah.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Being a watch guy, you'll probably appreciate that. But that was the only source of illumination they had. So in order to keep the brushes very fine, they were literally dipping it in the radium paint. And then after each brush, they were licking the brush to keep the tip real fine. And so they were ingesting bits of radium.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So there were a number of cases where they ended up, the radium is metabolized like calcium. So it was actually incorporating into the mandible and they were getting osteoradionecrosis of the jaw and things like that. So all of these different phenomena added together became a big deal because prior to that, people were using radiation for all kinds of crazy things.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It was in suntan lotions and waters and there was something called vigoridine that they were using for ED that you could... topical salves that had radiation in them. It was literally no end to it. And then when all the sequelae started to come out that, hey, maybe this isn't such a good idea, that's when things took off.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But now that we look back, the reality of it is, is that a lot of that was really overblown, even so much so that those radium dial painters, which we hear about this from day one in our residency training, there was only a small percentage, like I think 50 out of 1500, roughly, that actually had toxic sequelae. So most of them didn't.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yeah, I'm not sure what the reason is. They are inversely proportional to each other. I don't know that, I guess I'm probably not enough of a physicist to answer that question precisely. But having said that, that is the characteristic of this. And in doing so, that's one of the big reasons why all the fallacies about your cell phone giving you brain cancer and all are just that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And that's the thing, you know, they've licked different ways, but there have been some basic ideas. It was, again, we're talking about at that era, it was probably a couple of millisieverts to that particular area, but it was daily for decades.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so part of the reason why, if you actually look at the numbers, it was probably a super high exposure, but when you spread that out over such a long period of time, that's sort of the general trend. Like I mentioned earlier, it's not just the dose, it's the dose over time. The denominator matters a lot. And so that's why most of them actually did very well.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They even used to use radium internal nasal applications in the 19, I guess, 1920s to 1940s, essentially a radiation equivalent of a tonsillectomy or adenoidectomy. And it was done in something like a half million to two million children in the US and even in the armed forces. It was done routinely back then. And there's been very few adverse sequelae that were reported.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I don't even know what the dose was, but it was high. So there's a lot of cases where the exposure based on our 50 millisievert rule we talked about would just make people fall out of their chair. The actual reality of it is, is that many times the actual end results aren't as bad as we had expected.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yes.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Right. Right. I can tell you so many stories. You know, I got patients who I've had to treat. I had actually had a guy who was involved in nuclear testing at Los Alamos in the 1940s. He's passed away now, but I saw him in his 80s. So this was in the early 2000s. This was 60 years after that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They had very little monitoring back then, but he was close enough to feel the heat from a thermonuclear bomb. And by the time I saw him, he had had thyroid cancer, as you would expect. He'd had one or two lymphomas. I think I ended up treating his prostate. So he'd had at least four or five different malignancies. But the guy was as functional as most 80-year-olds are.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The guy was still walking and talking and doing just fine. And it actually seems that when you look at the population studies that were done outside the blast at Hiroshima and Nagasaki when, of course, the initial concentration, everyone dies from the thermonuclear energy.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But as you get several miles out, not only are the cancer rates actually roughly the same as the background, you actually see, again, evidence of hormesis where you have some patients in whom, or maybe not hormesis, but some sort of radio protection where you actually have lower rates of leukemia and thyroid cancer when you get a few miles farther out than you did in the general population.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So it's all very much dose dependent, time dependent. But I think the human body, we're evolved really to handle this to a larger degree than we realize. Because again, mammalian DNA, we came from the background of the animal kingdom where there was tons of exposure from natural cosmic rays and whatnot. And then our predecessors had to be able to survive.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They're fallacies because even having a cell phone on your ear for hours a day, it's non-ionizing radiation. And standing too close to a microwave oven, again, non-ionizing radiation. So that cannot damage your cells.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Our DNA had to be somewhat resilient in order to get to this point. I think it's more resilient than a lot of people give it credit for.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So prior to probably 1970 or maybe 1980, it was very prevalent even in the US. It was very widely done. Everyone, I talk to them about it now, it sounds like I'm doing something experimental and radical. But if you go over to Germany, again, going back to ankylosing spondylitis papers in 1898, they do something like I hear between 20 and 50,000 patients a year in Germany.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's mostly observational studies. There's very few randomized trials. But low-dose radiation for tendinitis, osteoarthritis, plantar fasciitis, all the itties you can think of, bursitis, a low dose of radiation has a similar anti-inflammatory effect to what you would get from a cortisone injection. And let's define the dose.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So now we're talking about very low dose, meaning 50 centigrade or 50 rads given six times over two weeks. So three gray, 0.5 times six is three gray to the affected joint using a very low energy machine. So this is especially in the case of someone who's got a hand, you're talking about electron beam radiation. Sorry, let me just make sure I got that straight.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Three gray, six fractions of half a gray each. So all six fractions combined is about the dose of one fraction for a typical cancer. That'll give you the idea. And giving it in a superficial fashion, where especially if it's a hand, you only have a couple centimeters of thickness. So we use what's called electron beam therapy.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The same linear accelerator, when the electrons go and hit the tungsten target and make photons, if you remove the tungsten target, you just get direct electrons. And electron energy can be modulated to where you can treat a superficial skin cancer. You can treat a knuckle. I can treat a temple, squamous cell, and not go into the brain.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
In the old days, before they had linear accelerators, I told you this goes back to the turn of the previous century, they had orthovoltage machines. And these basically created kilovoltage x-rays, not the megavoltage x-rays we use now. And all they could do was superficial stuff back then. And that's where it works very well. The dosage has changed tremendously.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But these days, the biggest data comes out of Germany, half a gray, three times a week, Monday, Wednesday, Friday for two weeks, just to the affected joint. And it has an anti-inflammatory effect very similar to either a cortisone shot or an NSAID. And how many weeks is the course? Two weeks. Monday, Wednesday, Friday, six treatments. And the protocol is what we typically follow.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The German protocol is to wait 12 weeks. And you usually see, depending on the joint, somewhere between a 60% and 80% success rate where the pain is, if not zero, at least markedly decreased. And then after 12 weeks, the German protocol allows for a retreatment. And then at that point, you get up to 90 plus percent success in terms of reducing pain. And this is for joint arthritis?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So arthritis, tendonitis, bursitis, plantar fasciitis is a really big one now that we're doing a bunch of. I've done probably close to 70 cases across the board just this last year.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Correct. It can excite the molecules, but it won't actually eject an electron, which is what would cause an ion to form, which is why it's called ionizing. And that's where we deal with on the, I'm on the therapeutic end. So diagnostic radiologists deal with lower energy x-rays than we do The very high energy X is what we use in our linear accelerators to treat cancer.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Many times for years. And in fact, my biggest cohort recently, which is still relatively new, I haven't done thousands of patients. Like I can speak from decades of experience with cancer. We're talking about dozens to hundreds. A couple of surgeons that were having trouble standing and operating. They literally couldn't perform their normal duties.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Six treatments to the fascia and they're walking like nothing ever happened. How long after the last treatment did it take? In the case of plantar fasciitis, it was almost immediate, within a week. I have other cases, especially when we do like knee arthritis, if there's a lot more pathology going on in a knee. I treated my own Achilles, which I can tell you about, took two months or so.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I was almost wondering if it was going to work or not. I was my own first patient. Before I offered to anybody, I treated my own achilles. Like a true doctor. Physician, heal thyself, right? And so I literally jumped on the table because a colleague of mine had posted about it. He's a radiation oncologist in Florida. He tried it out. And so I was like, you know, I have the machine.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I know this should work in theory. We just never taught about it in residency. Then I look at all the German data. There's tons of it. It's like, why do we not do more of this? And sure enough, I'm actually my own personal case control study because I did steroids and PRP in my left Achilles. And then later on this past year, did the right side with only radiation and no steroids.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And now I'm walking without a limp. You obviously did the other side. No, no, actually I didn't. The PRP actually finally did. So I had two cortisone shots and PRP in the left. And then a year later, radiated the right. Both of them are holding up pretty well so far. Got it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's still the same protocol. It's the three gray over six treatments over two weeks. Exactly. For any type of an arthritis, you're essentially lysing all the macrophages and you're eliminating that cytokine storm that would have normally resulted. It's very similar to what cortisone does, but the difference is it seems to be based on the study.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We've seen this much longer lasting than a cortisone shot. Not to mention the fact that you're not necessarily violating the capsule. And in the case of an Achilles tendon, you run the risk of rupturing it with multiple injections. So totally non-invasive. You just get up on the table. Most of my patients go right back to whatever they were doing.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And many of them are actually quite athletic and they don't take any breaks during treatment. They just do what they do. They're still working out.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So that's the big difference there is kilovoltage versus megavoltage, but all of these are ionizing. Okay.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
There is some data for spinal osteoarthritis specifically. It's less robust than all the extremities. I've actually done a few cases and it's actually worked quite well. Medicare actually does reimburse for these things. The issue with the spine is it's such a multifactorial area where if you've got a nerve root compression or a disc issue, I can't fix that part of it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But there is limited data that I've seen out of Europe that did show some degree of relief, but it's not the 80 to 90% that we quote for the extremities. It's probably half that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It should. And it does. I've done a few of those. SI joints seem to respond quite well. And that's in the literature. That's included. So hips, SI joint, lumbar spine, those sorts of things, they are described. They're just not as routinely treated. There's not as the level of experience that we do have with everything else.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You could, but that's exactly what you don't want to do because you're basically trying to eliminate all the macrophages in the region. So you're actually better off treating larger fields. So it's the exact opposite of what we do with cancer therapy. And because the dose is so low, you're not really gaining anything by being too cute with the small fields. You actually want to treat the region.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's like almost like an abscopal effect for the whole area.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
From the insertion in the gap. In my case, part of the gap, the inferior gastroc was painful too. So I treated that entire region. The field was probably about that long, all the way down to the calcaneal insertion and even onto a little bit of the plantar surface of the heel.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Because again, when you're talking about these super low doses of radiation, if it was a sarcoma of that area, I'd be treating a tiny little area. But over here, we want to treat the whole region. Most radiation oncologists, if we talk to their experience treating an extremity, it's usually for a sarcoma.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So that's a whole different ballgame where you're giving 60 gray to someone who's had a sarcoma in their leg or something. And you have to worry about things like edema. You can have lymphedema of the distal extremity if you've radiated the whole circumference of a leg or something like that. But with these low doses, it doesn't affect any of that. So you do treat large fields.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So it'll be from the insertion of the Achilles all the way down. If it's a plantar fascia, the entire plantar surface of the foot. Another thing that we see a lot, which is not arthritis, is diputerans, contracture, and also the foot equivalent, which is Lederhose disease. I had to look that one up. That was a trivia question. But it's essentially... palmar or plantar fibrosis.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yeah, almost. Palliative cancer, not a high dose, but again, that's for fibrosis. Keloids, it works very well to get teenagers with big old golf balls hanging off their ear after getting their ear pierced and things like that. And so again, you're treating the fibroblasts. In that case, you use four gray times three treatments of 12 gray, relatively large dose per fraction.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And you can totally protect the brain. Totally, 100%.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the treatment has to be adjuvant after a surgical resection. If you just radiate an intact keloid, it's not going anywhere because you don't have the DNA mechanisms of a weak cancer cell that can be wiped out. So it's kind of like doing a lumpectomy. But obviously, if the surgeon just did the resection, the keloid's coming right back. The fibroblasts.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
fibroblasts go crazy and they roar right back. So in order to do it right, a lot of people do it and they have multiply recurrent keloids even after treatment. You have to do the first treatment the same day as surgery. So you're just not letting those fibroblasts get a chance to have any sort of a foothold.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So I would literally arrange it with the dermatologist to do the resection, send them straight to me. So we get the first dose in that day. And ultimately, the cosmetic outcome is as good as if they didn't have radiation. You'll see the scar wherever it is. We get sometimes kids that have had acne scars all over their chest that have these bumps everywhere and they were all resected flat.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So radiation dosage, there's a couple of different terms that we've talked about. The main one we talk about when we're talking about patient treatment is the unit called the gray. And that's an SI unit that essentially is joules of energy per kilogram of tissue. So that's what they call absorbed dose. So that's in tissue.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And you radiate them, they just stay flat. You don't see any sort of dermatitis from radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The data was showing some like one in seven people in the country are afflicted and the socioeconomic costs are massive. And there's also, you know, going to your whole quality of life and longevity bias. I mean, we're talking about something that can really affect someone's ability to exercise at all, and it can lead to exacerbation of other medical problems.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And private insurance too, yes, for the most part. Now, a lot of times, because it's relatively new, I'll have to get on there and do a peer-to-peer with the company, but I've had no rejections at all. Even for the spinal ones, which are a little bit, there's less robust data, but I've gotten everybody covered.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's a big reason why it hasn't caught on. I think there's a component of just you've got eight hours or 12 hours a day that the linear accelerator can run. We're busy with that. But one of the things is that because patients
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Unless it's a deep hip or something, for most of the superficial, for all the other joints, you can use one of those old-style orthovoltage machines that I mentioned earlier, like what they use in Europe. They still sell those here.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
There's a company called Extrol that still makes them, and they're perfectly acceptable for all the joint stuff, except for the very deep ones, like maybe a SI or hip joint. But you could have a small center set up, and those types of machines don't even require the shielding because the energy of the photons is very, very low. It's highly underutilized at this point.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And the Europeans have shown us the way. It clearly works. And America just has to catch up.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But it's truly exciting. I mean, I love treating cancer patients. It's really personally very rewarding to tell someone that they're NED, there's no evidence of cancer in their body anymore, their PSA is low, their mammograms look good. That's what's kept me going this long. But the amount of immediate relief we're seeing from all these inflammatory conditions right away, it's a night and day.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Patients come in one day, they can't grip a doorknob or lift a gallon of milk out of their fridge. And after six treatments, they can't and they think you hung the moon. It's an amazing thing.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Whereas when you're talking about exposure in the general, in the air and just in general exposure, it's in the air, we usually use the term sievert for that. And actually both those terms for the most part are equivalent. It's just that the sievert itself will take into account if you have different types of x-rays, different qualities of x-rays that have different degrees of
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You already said the answer. I'm just going to move to Austin. We're just going to do this full time and drive cars on the weekends. No, but seriously, there's an uphill battle because as I've been going out and trying to get the medical community in Houston aware of it, you have a lot of pushback because
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Number one, you've got orthopedic surgeons, podiatrists, hand surgeons who are looking at this like, number one, what are you doing? What are you talking? They look at me like I'm crazy.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And number two is like, even if this actually works, the concern is when someone's got maybe a knee arthritis that's been nagging them and maybe they're going to need a total knee at some point, their concern is, wait a minute, is this taking surgery off the table? Which it's not, by the way, because it's such a low dose. There's been plenty of cases of surgery after the radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's not an issue. Or you're taking away from like when you had your plantar fasciitis. I'm sure the podiatrists build something for when they do those extracorporeal shock treatments and steroids and whatever it is. It's a different paradigm that would potentially be taking away. A lot of doctors are very negative about it. Most of them at this point are very negative.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But I think that tide is going to turn just like anything else. It's just going to take a lot of education, a lot of time, a lot of
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
that I think you can have your cake and eat it too. The reason I say that is many times this is an adjuvant for other things. So if you've got a podiatrist that's doing all these PRPs and other things, I'm actually looking at starting a protocol. I just treated a nurse in Houston who's a NP who does stem cells off-label, but she does them routinely, has quite a big practice.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
We're going to look at maybe you can do radiation with adjuvant stem cell treatment because it's such a low dose. This may be the sort of combined modality thing down the road that we haven't really approached where there may be options to do other things still.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's what it looks like. You know, I've got the C61, which is the ICD code for prostate cancer, which is in most of my patients. We got the osteoarthritis codes. Now they just go right through, typically without any sort of problem. Some of the private insurances, you have to get on a peer-to-peer call. But all I literally will do is quote them a couple of the German studies.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Unfortunately, we got a little bit of a setback because there's only two randomized clinical trials that are both heavily underpowered, poorly run studies, just not well done. So that's been a little bit of a setback. And the randomized data may never come just because of the nature of this sort of thing. But having said that, that's not the obstacle anymore. It's really just public awareness.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And like you said, just like a guy that doesn't want a radical prostatectomy and wants radiation therapy for his prostate, he's got to be his own advocate. And the data is out there. The information is out there. There's a couple of big Facebook groups, and one is only diputerans patients. And they literally will post up, I've got this big nodule, what do I do? My surgeon wants to cut on me.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so there's actually a whole network now. So there's a lot more of that education going on. They've got big PDF files of doctors all over the US that will do diputerans radiation. So Diputrens is a little bit more commonly accepted, but as I'm slowly talking to these folks, they're going to migrate into their arthritis space as well.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
potential to be ionizing, that they have a quality factor you'll multiply it by. But for the most part, we use the term gray when we're talking about, for example, when I treat a prostate patient, they're going to get somewhere between 70 and 80 gray, but it's fractionated into small daily doses as to be tolerable for the body.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So I think it'll come and the general public has nothing but great positive outcomes from this.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
There's a lot of variability there, depending on what the actual anatomy that's causing it. If it's literally just a straight-up osteoarthritis case with no physical structural issue, I've seen cases... Now, again, I've only been doing this about a year, so I don't have the 25 years of experience I do with cancer, but I've talked to... There's a couple of doctors who do this routinely.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They've been doing it for 20 years in LA. One of them treated his own neck, shoulder, and spine. I think he's at 15 years out. Anecdotal, obviously, but never had to retreat himself. Typically, the German studies allow for two treatments, two retreatments. Because the dose is so low radiobiologically, I don't see any reason why you couldn't do it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I don't know about annually, but maybe every few years or something like that. But there seems to be a fair bit of data That a lot of patients who don't have other struck, like a knee that's bone on bone, it might only last a month or may not even work. But for the other ones, like the hands and all, it seems like it's certainly longer lasting than any sort of cortisone shot.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But I think months are very reasonable and probably years for most people.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So I've done three cases of rheumatoid arthritis and one guy that had a gouty arthritis as well. Because again, it's a systemic disease. I'm not going to pretend to be able to cure that with a local treatment. But to a single knuckle that's driving them nuts, it's still an inflammatory process. And yes, it works great for that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It won't reduce the deformation necessarily because a lot of that is longstanding.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I think there's no strong data to support that, but I don't see why it wouldn't work personally. And it definitely, from a purely palliative standpoint, just to reduce pain, it does work. You have to manage their expectations.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And then when we talk about male receivers like we're going to, that's really just a measure of exposure, not absorbed dose in tissue per se.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
How far down the arm do you irradiate? I base it on where the patient, if they palpate, and if they're getting pain down into the brachioradialis, and if it's radiating further down, I'll treat a larger field. Because again, there's no reason not to. Bigger fields are better. No need to be- And again, it's just six- Three gray. Three gray. Three gray. So, and again, that's three gray locally.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's to an area where there's no vital organs nearby. The total body dose is negligible. It's like getting a CAT scan initially for the rest of the body. So I would treat definitely the joint capsule and a little bit of the distal humerus and the proximal radius and whatever else. But if it's hurting larger, I'll just treat a larger field. In that case, we use opposed lateral beam.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the patient will just lay there. The beam will come in from one side and rotate around from the other side and we treat them both because that way we get the same type of homogenous dose we do with our cancer patients. I've actually done several piano players that have de Quervain's tenosynovitis in their wrist. Because when you're stretching to play those notes, I'm a musician as well.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
My musician friends are coming to me, the wrist pain is going away very quickly. My biggest patient cohort so far are former patients because they don't have radiophobia. They're like, I've been through 80 grade in my prostate. This is a joke. I'm bringing my wife with me. And half the times the wives sit there for their daily treatment anyway, and they start chatting in the lobby.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So we do the wife's hand the same time we're doing the husband's prostate. And for the most part, the hands, the wrists, the elbows, it's very rapid. In the case of the tendonitis, like my Achilles, it was a couple of months, but that's not outside of the window of what we've been conditioned to expect from all the German studies.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So it can be not as immediate of a relief as a steroid shot, but it does seem to be more durable.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I got a couple of, actually a couple of doctor buddies. We get together and jam every week or two. And one of them is actually a guy now who's actually got his own YouTube channel and Spotify. And he was actually a professional musician before becoming a cardiologist. So we may actually start touring again.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yeah, so a gray and a sievert, technically. If anyone's kind of old school, you listen to older stuff, you'll hear the term rads. A lot of people have heard of rads. So one rad is equal to one centigray. 100 rads is a gray. It's just an SI unit versus the old terminology. And a sievert is the equivalent, only it's in air, not in tissue. But a sievert is a gray?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But back in the day, we had a full doctor band, a full 70s rock cover band called Ultrasound. Those are the good old days. We used to play Journey and Rush and Led Zeppelin all day long.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Neil was a genius. So greatest drummer of all time, are you going with Neil? Are you going with Bonham? Neither because I went to college here at UT and that opened my entire eyes up to the world of jazz. So the jazz drummers can all drum circles around those guys in terms of pure technical ability.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But yeah, feel, rhythm, not necessarily being able to wow people the way the jazz guys can, but yeah, Neil and Bonham are both right up there on the rock side of things. Would you put them at the top of the rock list? I would put Neil first. I'm just partial to Rush. And a lot of that has to do with their music, not necessarily.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Now, Neil was obviously an innovator, but as a 16-year-old, I'm sitting there trying to imitate every single note on his drum solos, everything like that. Neil, number one, but Bonham and the new generation rock guys are incredible. The guys that grew up with Neil as an inspiration are You've got 12 year olds who can do this stuff in their sleep.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And then all these math metal bands, you got dream theater and things like animals as leaders. Some of these guys are doing things. I pride myself as a drummer on being able to analyze the music really well. It's getting to the point where it's almost more math than music. Like it's so intricate, the modulation of the time signatures and things like that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's actually getting beyond where even I'm having trouble understanding. it now.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's a fine line. Because when you think about it, music is just math with emotion added in. And it gets to a point where some of it is not appreciable anymore, at least not to me. Some of these guys love it. But that's where the jazz side comes in, where it's all about feel. But even the jazz guys will be extremely talented in terms of their ability to feel the beat and have it be
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
pleasurable to the ear, but they're doing such intricate things. And when you can balance those two things out, that's heaven as far as I'm concerned, when you can have the emotional side and also have be technically challenging and not just playing a straightforward. The straightforward stuff is great too, but it gets a little bit tedious sometimes. So we met actually driving.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It doesn't compare. It's not even close.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I want to go to Minnesota with him and do that ice class. Are you going on this run? I don't know if I'll be able to make it or not. I'm trying to. Yeah.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Well, I knew who you were because I've been a member. I've been a follower for years. I was like, that's Peter Attia over there. So luckily we got paired up in the same group and that's kind of where it started. It was totally random. I was actually just, it was a last minute thing. That was actually a level two. So I was like, you hadn't done the level one. Right, right, right.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So I was like, man, how did this guy get in here without even doing the level one? So having done that, I agree, especially those cars with the automatic transmissions and the turbo lag, not the greatest for drifting.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
You know, I think whenever anybody asks me that, I kind of think about it in terms of every three- or four-year-old boy is enamored by cars, but normal people just grow out of it, and some of us never do. My dad certainly liked cars. He taught me how to change my oil and whatnot, but he wasn't a fanatic like I am. So it just kind of started there, and then it got to a point where I was like,
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Parents will tell you the story. I was that four-year-old who could tell you at a car driving by if it was an Oldsmobile that had Cadillac hubcaps on it. Like, how the hell does this kid know this thing? I don't know where it just kind of clicked. Over the years, it was always just a nice release.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I guess being a mechanically oriented type person, I think if I didn't do medicine, I would have done engineering, which is why it's so impressive. What did you study in college? I was actually biology. I did a BA with art. So I did a lot of jazz studies at UT. So I was a music guy. Engineering just seemed fascinating to me.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I was always interested in medicine from day one, but I think that really the mechanical side of things, like knowing that every car's five gear ratios and what their torque converter lockup is and what their horsepower and torque is, it's just- And what posters of cars did you have on your wall? The same as everybody. Actually, no, because everyone had a Countach, right? I never had a Countach.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
See, I had a Countach. What did you have? I mean, they're cool. I would have like a Callaway Corvette, Miami Vice Testarossa, 928, which I'm almost done with my old 928, getting it back on the road. More of the domestic stuff and the stuff that's more attainable, Fox Body Mustangs, the five liter Mustangs of that era, really cool. C4 Corvettes back in that era when they were state of the art.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I mean, I loved watching Knight Rider, so I thought Pontiac Firebirds were super cool. Yeah.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Great car.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I've never driven a Countach. Have you? I have. It's one of those don't meet your heroes kind of things. It's cool, but it's kind of a POS too. The bar has moved a long way since then. It's for the experience.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's enjoyable because of the 80s campiness in retrospect. But even compared to its contemporaries, you look at an 80s 928 Porsche or even a Testarossa, those cars are beautifully driving, you know, long distance cruisers, super comfortable, compliant suspensions. You got good ergonomics. And the Countach is so awesome because it has none of that. It's awesomely bad.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Would love to have ridden in one, but I haven't driven one. It's a race car. You're basically just sitting on the ground with a carbon tub around you.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Are we talking about just three cars that's all you can have in your garage? No, no, no, no. These are your three grail cars. Okay. Okay. I would probably say, man, there's too many to choose from, but to go with, it's going to sound like a cliche, but McLaren F1. I mean, how do you not pick that?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's got to be there. I sent you the picture of me sitting in that one. Yeah, I was jealous. I was jealous. Oh my God. That would have to be number one, but then there's at least 10 that I could pick from Be Happy, but I would probably say... And one of them is one that I have a lot of experience with, which is the Ford GT. I just think that's one. Gen one. One of the all-time greats.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That's exactly right. At altitude, it could be double that. That's right.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I would probably pick stuff that's manual and somewhat analog. So I'd probably have to say Carrera GT, Porsche Carrera GT with an NA V10. They're unobtainium now, but they were reasonable of just a few years ago. And they're just, there's plenty of faster cars.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They're never making any more of those limited supply. Demand is never going to wane for those at least. I think when you look at other collector cars, like some of the pre-war stuff, it's going down because the target market is all unfortunately dying off. Those people aren't around and appreciate that. And that may happen at some point, I suppose.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
There's going to be a point where nobody cares about this. We'll probably be long gone by then. But the McLaren F1 is unattainable. And there's so few of them. That's in a completely different league than the other cars. But even like something like Ford GT, they made 4,000 of them. It's not that rare. Well, a few of them are gone. A lot of them are gone thanks to lack of traction control.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But still, I don't think they'll ever go down just because that era, I think the Gen 2, the current Ford GT, which is a twin turbo automatic car, will ultimately be eclipsed in value by the old one, even though right now there's still more. They're almost double or triple, but I think it's going to go the other way. So where would you put the 959 on this list? We talked about that a little bit.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's right up there. The only downside to the 959 is that it was so ahead of its time. That essentially is what a modern Porsche is now. So yeah, it's super cool. You've got the 80s campiness, the looks, but it's basically like driving a 993 turbo for the most part. It doesn't have that NA V8 or V10 sound. It's a turbocharged flat six, like everything was after it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
At that time, there was nothing like it. Do they have four-wheel steering as well? You know what? I think they did. It was so modern. So modern. Sequential turbos and even water-cooled heads. Those were all air-cooled Porsches back then. They managed to water-cool the heads. And now Canepa does a really cool version, a restomod version, but those never came to the U.S.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I think you know about that, right? It was the Bill Gates rule. Did you hear about that? I did know about this. Say more. Say more. I don't know all the details. I should have read it. But essentially, he was able to get the gray market to passage for these cars for some loophole. I don't know the details of it. And only after that were they able to import them into the US.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Of course, now that they're older, you can get anything under a 25-year rule. I like the oddball stuff like that. That's just unavailable. The 959, I would still put a click below the Carrera GT just because of that naturally aspirated F1 drive V10 that just sings, and the 959's motor doesn't have that level of character.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yeah.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And the interesting thing there is it's really based on a 60s design. It was a tribute. But Camillo Pardo, who was the designer for Ford, who basically reinterpreted it for the 21st century, kept that original character, but made it aero-friendly and was able to use all these hard points from the old car, but make it modern and basically upsize the car.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's quite a bit. Quite a bit. That's right. Per trip, actually. So that can add up. And I was actually talking to a pilot friend about this. They don't really have any limitation in terms of total exposure that requires them to be taken out of the air. A lot of them, they're forced to retire at 65, I think is the commercial requirement.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's like 110% size of the original that you could actually fit two people in because the original GT40s were tiny, and they apparently generated tremendous front-end lift in Le Mans. And the modern one, I've actually run it the Texas mile on an airstrip over 200 miles an hour. It's dead straight.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They did everything right without resorting to the modern cars with all the big wings and all the big downforce. It's just well-balanced. It is a beautiful, beautiful car. They just did everything right on that one.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It was.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Those cars, again, at that time, I liked them more than I do now, just because, again, the hybrid technology is leaving those kind of, they're a little outdated now. I think out of those three, I was personally, maybe I'm sounding like a Porsche fanboy, but the 918 was just stunning. Part of it was just the design, forget about the performance.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And it had an, again, NA V8, high revving, bespoke to that car, not in any other platform. And the electric component was just the gee whiz thing of the moment, which of course made it ungodly fast. But that NA V8 and the way the exhaust sticks out of the back.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Like that's a Trinity. That's like having, you know, F40, F50, Enzo, LaFerrari, same sort of thing. I mean, all of those cars were amazing. But since then, the interesting thing about that era a decade ago was that was probably the inflection point after which performance doesn't matter anymore. Who cares? We've saturated performance. Your traction limited at this point. Right.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And not only that, you can buy a used EV. You can buy a Tesla Plaid that'll do 60 in two seconds flat, 50 grand that'll smoke everything.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So I did an outlap.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the first hard break. First hard break. Is going into turn one. Going to turn one. And my buddy was in an SF90, which is a thousand horsepower Ferrari hybrid, which is basically the fastest Ferrari you could ever buy. I was catching up with him in 20 and coming down the front straight, I caught an SF90 in my daily driver.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But I nearly rear-ended him because the car was able to stop just barely for turn one, but the brake fluid boiled at that point. The car was not designed to do that, unfortunately. And what's interesting is you would say, okay, it's an electric car, it's heavy, blah, blah, blah. Other electric cars don't do that. The Lucid, the Taycan, they actually have really good brakes.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But they don't really monitor the actual exposure to that level twice. I think the reason they don't really use that as a limiting factor for the amount of work is really just that even though they get a higher dose, there's been no proven increase in cancer in those types of populations, even in flight attendants or anything like that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But at the time, I didn't realize this because they had been advertised as being track ready, or at least able to run a, like they're talking about how it ran so good at the Nürburgring. But the factory brake fluid is DOT 3. I find out after the fact, which is low boiling point, just boiled it. The car is designed for efficiency, low drag. By the way, I didn't even use DOT 3 in my simulator. Right?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Probably. boiler simulator. Yeah, yeah, yeah. So a 5,000-pound machine stopping from 100, and I probably did 160 on the front straight. I bet more. Yeah, well, that's about it. I think it was limited, actually, that time. It didn't have a track mount. The amount of BTUs that you're trying to shed off of those brakes, just forget about it. So thankfully, it had regen braking.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the brakes are fine if you put better fluid in? Well, they're better. They're less terrible. But if you want to track a plaid, you're going to need new brakes. Did I tell you what I did? I ended up having a full Wilwood setup put on the car. So all new rotors, custom ducting, Mike Dussault, Dussault Designs. Actually, he bought a plaid for himself.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
He's the guy that built the Z06 I'm driving now. But he ducted into the front brakes, basically custom brake ducts. That car is sealed. The whole front end is sealed. It's not meant for that. It's meant to just be low drag. So you weren't getting any air on them? Nothing, nothing at all. So he actually made custom ducting.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And after that, the car was unbelievable because you could actually late brake and do really well. So what lap time? can you do in a tripped Plaid now? Here's the problem. You can only get one solid lap before it starts pulling power due to heat to the battery. Okay. But my best was a 224. And so that's at a 5,000 pound car that's no weight taken out. This is a stock car.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I didn't do any mods to it other than just the brakes. But you do one lap just to re-answer your previous question. I don't know how much time we have, but I'll just keep it brief. That one stop turn one, brakes gone. Thank God I have regen. So I just literally nursed it. But I was already, I couldn't turn off. So I go through the S's and I'm just 30 miles an hour, whatever I got down to.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So coming through 9, 10, coming into 11. Again, I'm not on the throttle at all. I'm just maybe going 40 miles an hour. But the regen is coming down the hill towards 11. The regen has kept me from gaining any more speed. My right foot is on the floor. The fluid is boiled. So I had to go wide in 11 into the gravel, completely around.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And then, you know, that's when I found out about all that and the McLaren Senna both taught me where all those orange squares are spray painted on the arm coat where you can have the emergency offs. So I literally went through the gravel, came within inches of the arm coat 11, and then just hobbled in. But then after that, the next time out, we put Castrol brake fluid in it and changed the pads.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Then it was good for maybe a lap. So then ultimately that still wasn't good enough.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Or they're mostly Model 3s. The Model 3 is 800 pounds lighter. It's not as fast, but it's a way better track car. So I've got dozens of laps in Model 3s. They do fine because they're not making a thousand horsepower and they don't weigh 5,000 pounds. They still will boil their brakes.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The same way that people in Denver and the people here in Texas don't have any higher incidence of cancer.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But if you just do pads and fluid, that's actually a very desirable, especially if it's a little bit damp outside, not much can keep up with you in a Model 3. And autocrosses, they've won national championships with just coilovers in a 4,000-pound sedan. That's where EVs have gotten.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But just to answer the previous question, we did the brakes on the Model S. And then once that was done, the only thing that eliminated the brakes is the weak link, but the battery, the cooling is still not there. So you've got guys spending tons of money. I actually was looking at doing a really heavily modified aero Tesla Model 3 like Randy Pope's drives. It'll only do a lap at Koda.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's such a high speed and high braking, but you can hot pit and go right back out and you can keep hot pitting, but you'll never get a full lap time. But it'll do just fine if you do that. But the next gen cars, the Porsche Taycan, even the Lucid Sapphire now, those cars, they're just as heavy, just as powerful, and they can do it. Have you taken the Taycan Turbo S out?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I did when it first came out in 2020. And what'll that lap at? At the time, I was on stock tires and everything, probably 230-ish, right around there. Interesting. I think I probably sent you that video. At John Hennessy's track, I had the Taycan, the Lucid, and the Plaid all lined up on the drag strip.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I'm in a 750 horsepower Porsche that can run tens in the quarter mile, and the Plaid and the Lucid walked away from me like I was on foot. You just didn't have the traction control? No, it didn't have the power. 750 horsepower versus 1,100. How much does the Lucid have? This was the old Lucid. Now the new Sapphire Lucid has more, has 1,200, but this was 1,100.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And it's still a 10th or two behind the 1,000 horsepower Tesla.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And they're all all-wheel drive. The traction is a non-issue. All the same tire.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Power to weight.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
When you stand on a Turbo S, if there's a plaid next to you, he will leave you like you're not moving. That's like the Audi. It's a super fast car in the real world, but that's why horsepower doesn't matter anymore. But that was more horsepower limited. The Taycan would happily do, and actually I had a turbo before the Turbo S, which had steel brakes. Turbo S had ceramics.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And even the turbo would do it on all season tires. The very first Taycan that came out, this was in the early days when Porsche was, VW was having to respond to Dieselgate. You remember Dieselgate? So they had to build these electric cars and they had to go to states that were CARB, basically the California Research Board emissions compliant because of all the diesel penalties they had.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So the first cars didn't come to Texas. They only went to New York. So I got a non-turbo S, a regular Taycan, one all season tires out of New York and on steel brakes, Porsche's Porsche. I mean, it was squealing in the corners of an all-season tire, but it lapped 20 minutes. No problem. Brakes were solid. There's just something about the German engineering there.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But having said that, the Lucid is now equally good, if not better, despite being a brand new non-legacy company who is, again, not trying to build a track car. But the Lucid Sapphire is faster than a Plaid now. It runs eights in the quarter mile, but it can actually track. And even my old Lucid, which I was expecting to- It can run eights in the quarter mile? Eight nineties.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Yeah, it can crack in sub nine now. It's several car lengths ahead of a Plaid, which is beyond bonkers. You have to warn passengers. These cars now, you can't just accelerate on them. You have to say, hang on, just put your head against the headrest before I concuss you.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So my best, again, the biggest limitation of the- The tires. The non-GTR, the Senna GTR can probably, I've seen guys run like, I think, two flats in those things. I know a coach of mine had run a 208 just barely even trying. But the street Senna on the Trofeo R, it understeers. It's really just not meant for that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But it'll still, and it got tons of downforce, tons of braking, but it just doesn't have the grip. So I think the best I did was a 215. And again, when you're driving a car that value.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That is insane. Insane. But at the same time, I'm sure a pro could do better. I was still thinking, you know, that Armco gets really close to a car of this value. It could be a really bad day. Where were you breaking into turn 12? 150, even on Trofeo R's. McLaren doesn't want you to put slicks on it. And so I violated all the rules.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I ended up putting a set of Pirelli tires off the Ferrari Challenge cars on it. When I first put it again, slicks need camber. You can't get much camber out of a street center, which to me was the most disappointing thing, whereas the GTR, you got four degrees.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Even without camber, when I first stopped on that back straight, completely stocked center with just slicks on it, at the 150 mark, I almost parked it in the corner. It was incredible. Even with the Trofeo R, to stop at 150 in a car that, in a tire that drove me to Houston and back, The bandwidth of today's tires, that's a whole nother topic.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It's incredible what even an all-season Michelin can generate at 1G. 1G is nothing anymore. All my old car and drivers, I have a library of thousands of magazines. 0.8, 0.9 was a huge deal 30 years ago. Now you got minivans that do that. And even all-season shod sports cars that are heavy can do that on a regular tire. The chemistry of these tires these days is unbelievable.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Right.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
AMG GT3. I was running hand cooks, which would at least last me two weekends. And even then, like that car was running two 11s on hand cooks with just me driving it. So the pros are running faster than that. Yeah, I think Senna GTR, not a street car, of course, but just... The problem with the Senna street car is it's two track for the street and it's two street for the track.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
A 720S, which is mechanically identical without all the downforce, is a beautiful GT car. Drive it cross country, you can store stuff in it, super comfortable. And on Hoosiers, not on slicks, but on Hoosiers, and I changed that to steel brakes, that's a 216, 217 car. It's not that much slower.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That one, I'm sure, I think Randy Popes could probably run close to that. But driver to driver. Driver to driver, three seconds probably. And that's all in the straights because the GT4 car has half, not half the power, but it has, and actually my GT4, I cheated. I tuned it. The 570S GT4 was already detuned from the street car, but you can tune the street cars as well.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Not at all. And so it depends on what type of radiation we do. Now, typically for our external beam machines, we're doing it all remotely from behind a shielded wall. So the vault in which the machine is placed is custom built just to shield based on the angles that the machine can move through.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So when I was, I pushed an extra 150 wheel just by tuning it because stock turbos can handle that. So that would go 175 on the back straight, whereas a regular GT4 can do 20 miles an hour less than that. But even then the 720S, actually 720S and Senna are identical on the back straight. The Senna can stop later though. Stop later. Yeah. The Senna, you can stop on, you can wait till 100. Yeah. Yeah.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
In the 720 with the aftermarket steel brakes, pads, and a Hoosier, which is still a DOT tire, you could still break it a little bit after 200. It's not bad at all for a car that you can go shopping at the outlet malls in because it's got a massive frunk. And the ride compliance, that
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
the biggest thing about mclaren so the scent is more tied down but they all have that active suspension that doesn't use sway bars or springs it's all hydraulic it's all fully active there's hydraulic lines that diagonally connect the front right to the left rear wheel so the pressure in those lines combats body roll so you can have it be a plush highway ride or you can have it be a
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
stiff track car. The bandwidth is almost unobtainable in any other car.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Is that what you're talking about primarily? They are. Yeah, they truly are. And a big problem is, I think, is the perceived, I mean, actually, it's not just perceived, the actual lack of reliability. I love the cars, but they're always, it's all the jokes about British electronics. They all come to bear. Even the Senna would go into limp mode on between nine and 10.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
If you floor it, it wasn't just mine. We had Senna Fest going on with 20, I think we had 20 on track at one time. Some guys were just kind of tooling around, so they were fine. But if you were hauling ass between nine and 10, when you get a little bit of suspension droop, you're going to limp mode. If you're accelerating through that, I would literally- Even a GTR? No, no.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I'm sure the GTR is fine. I haven't tracked one of those, unfortunately.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
That was in track mode. I think it happened to me even one time I forgot to put it in track mode. I think it still did it. It's a G-Force related to suspension droop issue. They just freaked out the computer. And they had McLaren guys on site who were actually working on patches. And they could patch it? They did. I think it made it less frequent, but I think it still happened after the patch.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I'll have to ask the McLaren guys about that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
If there's like a direct angle where the machine is hitting a wall, that wall has to be built 10 times thicker than the walls where the beam can't reach. So essentially our dose... when treating remotely is close to zero.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I really appreciate the offer to come out. This is a true privilege. Peter, what you have done in this community is unparalleled in terms of, I think I told you when I first met you, I was like, dude, how do I get CME for this stuff? Your lectures are better than almost all, not lectures, but your podcasts.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
are better than almost all the CMEs because you get the right quality people on here, much better than me by far. And the way you phrase the questions and the way you parse everything, it's so understandable for a wide bandwidth. I got my non-medical friends and family all the way to the colleagues. Everybody gets something out of them, and that's hard to do.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I think we have a whole indication for a whole separate series here that truly is the drive. All right. Well, thank you, man. Thank you, Peter.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
So we keep film badges, but it's almost become kind of a joke that when we're not doing brachytherapy, which is dealing with actual live radioactive sources, our exposure is super low, almost negligible, really.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But back when I was in residency doing a lot of GYN implants and things like that, where you're putting cesium or iridium actually into the body cavities, and you're actually up there putting it in up close, we had a ring badge on. And as a resident, we'd rotate every month. But if we didn't rotate, some of the faculty actually got pretty high doses. Any idea what the sequelae of that was?
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
I know of a couple of folks, the ones who did a lot of GYN therapy, especially in the older days, we're talking about in the 80s and the 70s, where you could actually see dermatitis on their hands from doing that, just from the hand exposure. One of my faculty members actually had a giant cell tumor of the bone in her finger. And again, this is after decades and decades of doing it.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
It was a benign growth, but that was a real thing. There's a lot of Data out there on especially people who were dealing in x-ray for dentistry and stuff like that back in the day when they didn't have shielding or anything like that, that they would get dermatitis.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
The most common thing you'd see is skin irritation in that sort of situation, dermatitis and even some chronic flaking and things like that.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
They certainly do because you have to use more energy to get into a larger person. Having said that, there's two different things here because what we normally deal with when I'm talking about dose to a tumor is the dose actually at that spot versus a whole body dose, which is a very different metric.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so for someone who I'm treating with, say, eight weeks of radiation for prostate cancer, their prostate may get 80 gray in 1.8 to 2 gray fractions per day, but that's literally only to a small volume, roughly the size of the prostate gland itself.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And when you even get just a few millimeters away from that, that dose gets cut in half and then it's exponentially lower because the intensity of the radiation varies with the square of the distance. So as you get even a couple of feet away, that goes down significantly. But typically a patient who is getting 80 grays, if 80 gray was a whole body dose, that would obviously be lethal.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
But the whole body dose is more like a few milligray in that sort of situation. So we typically don't see full body sequelae or anything from doing even the heavy duty diagnostic treatment. Now for the CT scan, we almost consider that negligible in our area because again, I'm dealing with mega voltage, high dose cancer killing radiation.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
And so when they get a CT scan, which is going to be just a few millisieverts or milligray, that's almost considered rounding error. Versus what they're getting to the tumor area.
The Peter Attia Drive
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
Normal size person, it's a fraction. It's probably less than one millisievert actually. So it's significantly, it's something that where people who are concerned about things like diagnostic mammograms and all every year, you're still talking about maybe one millisievert or even a little bit less than that with some of the newer machines.